Format

Send to

Choose Destination
Blood Cancer J. 2018 Jun 11;8(6):55. doi: 10.1038/s41408-018-0081-8.

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

Author information

1
Yale University and Yale Cancer Center, New Haven, CT, USA. amer.zeidan@yale.edu.
2
Yale Cancer Outcomes Public Policy, and Effectiveness Research (COPPER) Center, New Haven, CT, USA. amer.zeidan@yale.edu.
3
Yale University and Yale Cancer Center, New Haven, CT, USA.
4
Yale Cancer Outcomes Public Policy, and Effectiveness Research (COPPER) Center, New Haven, CT, USA.
5
Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.
6
Department of Chronic Diseases, Yale School of Public Health, Yale University, New Haven, CT, USA.
7
Department of Health Policy and Management, School of Public Health, Yale University, New Haven, CT, USA.
PMID:
29891916
PMCID:
PMC5995881
DOI:
10.1038/s41408-018-0081-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center